HansBiomed Corporation (KOSDAQ:042520)
South Korea · Delayed Price · Currency is KRW 19,500
+440 (2.31%)
At close: Aug 20, 2026
HansBiomed Financials Overview
Financials in millions KRW. Fiscal year is October - September.
Millions KRW. Fiscal year is Oct - Sep.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Revenue Revenue Growth | 124,812 | 89,780 | 81,137 | 78,032 | 74,459 | 59,098 |
Revenue Growth | 45.85% | 10.65% | 3.98% | 4.80% | 25.99% | -26.22% |
Gross Profit Gross Profit Growth | 74,648 | 51,514 | 51,747 | 45,123 | 45,683 | 29,229 |
Operating Income Operating Income Growth | -18,353 | -27,891 | 625.6 | -4,155 | 1,256 | -19,778 |
Net Income Net Income Growth | -19,665 | -31,341 | -7,223 | -23,045 | 6,147 | -18,289 |
Earnings Per Share EPS Growth | -1432.07 | -2413.29 | -558.00 | -2150.23 | 180.37 | -1827.00 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Human Tissue Section Human Tissue Section Growth | 73,783 | 51,985 | 48,980 | 43,373 | 34,029 |
Medical Device Division Medical Device Division Growth | 46,921 | 55,495 | 54,834 | 54,586 | 43,791 |
Other Section Other Section Growth | 7,757 | 6,263 | 5,207 | 4,323 | 4,230 |
Unallocated Adjustment Unallocated Adjustment Growth | -38,681 | -32,605 | -30,989 | -27,824 | -22,952 |
Total Total Growth | 89,780 | 81,137 | 78,032 | 74,459 | 59,098 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Cash & Investments Cash & Investments Growth | 19,623 | 8,149 | 7,259 | 7,048 | 13,553 | 20,268 |
Total Debt Total Debt Growth | 42,144 | 43,307 | 36,430 | 41,141 | 55,910 | 51,577 |
Net Cash (Debt) Net Cash Growth | -22,521 | -35,158 | -29,171 | -34,093 | -42,356 | -31,309 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -1640.11 | -2707.17 | -2252.56 | -3181.12 | -3224.39 | -3127.17 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -15,640 | 318.34 | 1,759 | -3,733 | -4,270 | -14,645 |
Capital Expenditures CapEx Growth | -2,782 | -1,862 | -2,594 | -1,937 | -3,986 | -4,891 |
Free Cash Flow Free Cash Flow Growth | -18,421 | -1,544 | -835.74 | -5,670 | -8,256 | -19,535 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
Gross Margin | 59.81% | 57.38% | 63.78% | 57.83% | 61.35% | 49.46% |
Operating Margin | -14.70% | -31.06% | 0.77% | -5.33% | 1.69% | -33.47% |
Pretax Margin | -14.57% | -33.14% | -8.17% | -30.16% | 4.70% | -36.58% |
Profit Margin | -15.75% | -34.91% | -8.90% | -29.53% | 8.26% | -30.95% |
FCF Margin | -14.76% | -1.72% | -1.03% | -7.27% | -11.09% | -33.06% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 20, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 |
PE Ratio | - | - | - | - | 15.12 | - |
Forward PE | 12.43 | 13.87 | 13.87 | 13.87 | 6.95 | 6.95 |
PS Ratio | 2.23 | 2.63 | 1.58 | 2.66 | 1.25 | 2.72 |